( April 4, 2025, 23:31 GMT | Official Statement) — MLex Summary: Lupin and Zydus Pharmaceuticals filed counterclaims in Astellas’ patent case, accusing it of maintaining a monopoly over the market for the active ingredient of Myrbetriq by manipulating the patent process to strategically time the issuance of duplicative patents and by repeatedly filing successive and duplicative patent infringement actions based on patents covering the same or similar subject matter, which actions and patents are designed to interfere with generic manufacturers entering into the market.See attached files….
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.
